BioLife Solutions (BLFS)
(Real Time Quote from BATS)
$23.00 USD
+0.12 (0.52%)
Updated Aug 7, 2024 09:54 AM ET
4-Sell of 5 4
F Value C Growth B Momentum D VGM
Income Statements
Fiscal Year end for BioLife Solutions, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 143 | 162 | 119 | 48 | 27 |
Cost Of Goods | 97 | 108 | 82 | 21 | 9 |
Gross Profit | 47 | 54 | 37 | 27 | 19 |
Selling & Adminstrative & Depr. & Amort Expenses | 118 | 199 | 71 | 33 | 19 |
Income After Depreciation & Amortization | -71 | -146 | -34 | -6 | 0 |
Non-Operating Income | 5 | 1 | 6 | 5 | -3 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -66 | -145 | -28 | -1 | -3 |
Income Taxes | 0 | -5 | -20 | -3 | -2 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -66 | -140 | -8 | 3 | -2 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -66 | -140 | -8 | 3 | -2 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -59 | -129 | -21 | -1 | 2 |
Depreciation & Amortization (Cash Flow) | 12 | 16 | 13 | 5 | 2 |
Income After Depreciation & Amortization | -71 | -146 | -34 | -6 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 43.72 | 42.48 | 38.50 | 27.31 | 22.03 |
Diluted EPS Before Non-Recurring Items | -1.04 | -0.69 | -0.55 | 0.01 | 0.08 |
Diluted Net EPS (GAAP) | -1.52 | -3.29 | -0.20 | -0.03 | -0.09 |
Fiscal Year end for BioLife Solutions, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 31.73 | 32.73 | 33.33 | 39.51 |
Cost Of Goods | NA | 19.17 | 23.48 | 21.68 | 27.70 |
Gross Profit | NA | 12.56 | 9.25 | 11.65 | 11.81 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 22.68 | 22.41 | 40.43 | 27.09 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -10.12 | -13.16 | -28.78 | -15.28 |
Non-Operating Income | NA | 0.25 | 0.24 | 0.24 | 5.51 |
Interest Expense | NA | 0.21 | -1.31 | 0.48 | 0.42 |
Pretax Income | NA | -10.09 | -13.43 | -29.02 | -10.19 |
Income Taxes | NA | 0.13 | -0.04 | 0.12 | 0.01 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -10.22 | -13.38 | -29.13 | -10.20 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -10.22 | -13.38 | -29.13 | -10.20 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 45.43 | 44.82 | 43.57 | 43.44 |
Diluted EPS Before Non-Recurring Items | NA | -0.19 | -0.22 | -0.34 | -0.24 |
Diluted Net EPS (GAAP) | NA | -0.22 | -0.30 | -0.67 | -0.23 |